Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololBjörn Dahlöf, Hans Wedel, Richard B. Devereux et al.|The Lancet|2002Cited by 5.4k
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialPeter Sever, Jan Östergren, Björn Dahlöf et al.|The Lancet|2003Cited by 3.8k
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialBjörn Dahlöf, Jan Östergren, Peter Sever et al.|The Lancet|2005Cited by 2.9k
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLars Lindholm, Steven Snapinn, Hans Ibsen et al.|The Lancet|2002Cited by 1.6k
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysisKazem Rahimi, Barry R. Davis, Takayoshi Ohkubo et al.|The Lancet|2021Cited by 997